Kelonia Therapeutics reported in‑vivo CAR‑T data at ASH demonstrating efficacy in multiple myeloma with a single infusion of an off‑the‑shelf in vivo CAR‑T approach. Company presentations suggested measurable tumor responses and supported the expanding interest in in‑vivo CAR platforms that aim to simplify manufacturing and broaden patient access compared with autologous CAR‑T. Kelonia’s results add to a growing dataset across the field that seeks to validate in‑vivo delivery as a pathway to scalable cell therapy. The company emphasized potential advantages including single‑dose administration and reduced logistical complexity for centers that cannot support autologous cell manufacturing. Clarification: In‑vivo CAR‑T approaches deliver genetic constructs directly into patients to program T cells inside the body, potentially avoiding ex vivo cell processing and lengthy manufacturing.